<DOC>
	<DOCNO>NCT02005900</DOCNO>
	<brief_summary>Highly active antiretroviral therapy ( HAART ) able cause lipid metabolism glucose homeostasis alteration , associate redistribution body fat . Alterations lipid carbohydrate metabolism contribute development highly atherogenic profile , together alter fibrinolysis marker increase presence proinflammatory cytokine blood ( especially tumor necrosis factor alpha ) come associated success HAART cause development accelerate atherosclerosis . Docosahexaenoic acid ( DHA ) polyunsaturated fatty acid demonstrate ability reduce triglyceride level ; modify cholesterol fraction increase size LDL particles thereby configure less atherogenic plasma profile . Additionally , administration DHA show antiinflammatory hypotensive activity , contribute reduce risk cardiovascular complication patient . At molecular level , DHA act stimulator nuclear receptor PPAR-gamma , describe induce increase adipocyte differentiation . Furthermore , anti-inflammatory effect induce DHA , decrease elevate level TNF-alpha , implicated pathogenesis body fat redistribution HIV infect patient undergoing HAART . Therefore , hypothesis project DHA able produce lipid-lowering , anti-inflammatory , hypotensive profibrinolytic effect , together improve atherogenic profile patient HIV-1 infection receive HAART . In addition , propriety PPAR agonist improve redistribution body fat present many patient . The study activity DHA dendritic cell monocytes indicate absence immunosuppressive effect DHA context HIV-1 infection . In summary , DHA natural product , omega 3 polyunsaturated fatty acid , therapeutic property describe recent year show cardio-vascular metabolic beneficial effect , without recognize side effect . The highly purified DHA administration high dos could able reverse , least partially , lipid abnormality associate HAART exert beneficial effect fat redistribution HIV-infected patient treat HAART . To ensure non deleterious immunological treat sensitive poly-medicated patient , substantial change functionality dendritic cell monocytic study .</brief_summary>
	<brief_title>Effect DHA Lipid Carbohydrate Metabolism Alterations Body Fat Distribution HIV Patients Under HAART .</brief_title>
	<detailed_description>Hypothesis : DHA treatment would able revert , least partially , lipid disturbance associate HAART improve least bad fat redistribution associate HAART , without induce derangement dendritic cell monocyte functional ability . Variables : effect DHA treatment total cholesterol fraction , triglyceride , insulin , fibrinolysis marker , tumor necrosis factor alpha ( TNF-α ) , fat distribution assess anthropometric measurement , bioimpedance , sonography , DEXA abdominal CT . Effects DHA administration phenotype functional capability dendritic mononuclear cell . Objective : To determine treatment high dos highly purify docosahexanoic acid ( DHA ) able revert , totally partly , lipid disturbance fat redistribution associate highly active antiretroviral therapy ( HAART ) , effect phenotype function dendritic cell monocytes Data analysis : Baseline data analyze good balance . Fisher´s exact test use ass difference categorical variable , Student 's test continuous variable , Mann-Whitney test ordinal variable . The main efficacy variable difference baseline final value use MANCOVA model take baseline value covariable . Efficacy assess contrast adjust mean end study group treatment . Intention treat analysis use . The methodology perform center clinical trail conduct following : After obtain informed consent , patient 's baseline examine collection demographic data , HIV infection status , pharmacological data , anthropometric parameter , proceed conduct complementary examination design identify define body fat composition , body fat distribution perform basal analysis include parameter previously mention . It also evaluate hygienic-dietetic habit patient special attention alcohol intake , physical activity concomitant medication . This procedure carry make retrospective diary last 7 day . The patient 's daily caloric intake quantify Nutrilogic ® software ( Bio Logic , Barcelona , España ) . Physical activity quantify Minnesota scale ( Elosua R , Marrugat J , Molina L , Pons S , The MARATHOM Investigators . Validation Minnesota leisure time physical activity questionnaire Spanish men . Am J Epidemiol 1994 , 139 : 1197-1209 ) . Body fat composition body fat distribution : do follow additional test : Densitometry DEXA : Will determine patient supine position leg straight foot together , standardized examination table densitometry device ( Lunar Prodigy , Madison , WI , USA ) . In initial study enerarán face different region copy transferred image subsequent study reduce variability successive determination . There perform body fat measurement , body composition assessment bone mineral density dual absorptiometry technique . There performed total body `` scan '' ( body composition ) focus lumbar spine ( trabecular bone ) proximal third femur ( cortical bone ) evaluation last two case bone mineral density possible osteopenia osteoporosis . Abdominal CT : Will obtain perform spinal digital radiography , latero-lateral view , locate L4 get tomographic section pass center vertebral body . Subsequently , digital calculation intra-abdominal fat subcutaneous fat , manually select area interest . The area measure do cm2 . Lab analysis : blood sample biochemical determination obtain Vacutainer tube 10 ml without additive . Blood clot room temperature 30 minute centrifuge 2500 rpm 15 minute . After separate serum clot ( 4-5 ml ) , divide 1 aliquot 1.5 ml ( study lipid ) 5-7 aliquot 0.5 ml aliquot freeze -20 °C biochemical analysis carry . Plasma lipid , glucose , glycosylated hemoglobin , insulin C-peptide : measurement total cholesterol triglyceride perform use automated trading method ( enzyme colorimetry , Roche Diagnostics ) adapt automated autoanalyzer Hitachi 911 . The determination apolipoproteins AI , B C-III , lipoprotein ( ) hold mediate commercial method ( immunoturbidimetric assay , Roche Diagnostics Wako Chemicals ) adapt automated autoanalyzer Hitachi 911 . The determination cholesterol lipoprotein fraction ( Lipid , ELIP ) ( VLDL , LDL , HDL ) perform follow method : VLDL separate ultracentrifugation flotation , cholesterol HDL determine direct method ( Roche Diagnostics ) cholesterol LDL determine difference total cholesterol VLDL HDL cholesterol fraction . Glucose : commercial method ( enzyme colorimetry , Roche Diagnostics ) adapt automated autoanalyzer Hitachi 747 . Serum insulin concentration determine non-competitive chemiluminescent enzyme immunoassay ( Immulite 2000TM , Diagnostic Products Corp. , Los Angeles , CA , USA ) . The serum concentration C-peptide determine non-competitive chemiluminescent enzyme immunoassay ( Immulite 2000TM , Diagnostic Products Corp. , Los Angeles , CA , USA ) . Determining size LDL particle : The size LDL particle determine total plasma use acrylamide gradient gel electrophoresis nondenaturing condition . Will use standard four know LDL diameter band , previously determine electron microscopy . Determination fatty acid plasma : Treatment compliance corroborate determine fatty acid composition plasma lipid gas chromatography . Plasma total lipid extract method Bligh Dyer chloroform : methanol ( 2:1 , V : V ) . Methyl ester fatty acid obtain transesterification boron trifluoride methanol 80 °C 60 min . allow high recovery lipidic compound include PUFAs . Aliquot contain methyl ester fatty acid analyze gas chromatography device ( Hewlett-Packard model 5890 ) 30 m. RTX-2330 column ( Restek , Bellefonte , PA ) internal diameter 0.25 mm equip flame ionization detector . The carrier gas helium pressure 105 kPa . To total separation different compound provide two temperature setting : 140 °C-200 °C 3 °C/min two stage 140°C-180°C 4°C/min 180°C-210°C 2°C/min . The temperature injector detector 260 °C . The linear response detector test periodically standard mixture . Typically , two internal standard different molecular weight ( 13:0 23:0 27:0 ) use . Peaks integrated integrator D-2500 ( Hitachi Ltd. , Tokyo ) identify comparison retention time standard . When necessary , identification may confirm mass spectrometry ( Hewlett-Packard detector model 5970B ) ionization potential 70 eV . Study marker inflammation : blood withdrawn 5 ml EDTA tube . After extraction , tube centrifuge , plasma collect eppendorf tube frozen -70°C cytokine determination . The content TNF-alpha , IL-1 beta IL-6 plasma sample measure ELISA . Each sample analyze duplicate use ELISA kit `` R &amp; D Systems '' follow specification commercial supplier . Intervention : Patients randomize one two treatment group ( placebo DHA ) , use centralize randomization list . The study conduct accord double-blind trial methodology , neither patient physician unaware active substance administer patient . The randomization procedure perform assign either strategy accord randomization scheme generate module PROC PLAN SAS ( version 8.2 ) multiple 2 block follow pattern 1:1 stratify center . A list random assignment generate accord mention , issue seal opaque envelope , identify sequential number name center . The envelope shall deposit center central data management analysis , act coordinator centralized randomization assignment telephone contact . Patients evaluate inclusion study , personal data collect specific collection data notebook . After informed consent procedure patient consent include study , centralize randomization assignment center contact . When patient data register , envelope open strategy assign patient report investigator . The procedure shall transcribe document contain envelope , sign date register person responsible central randomization center . Capsules identical external appearance contain oleic acid ( placebo ) docosahexaenoic acid dose 500 mg per capsule previously prepare . The capsule coat protective cover make taste imperceptible patient . The dosage DHA 4 g daily . At interval , patient placebo group take 4 g daily oleic acid . Data collection : The data patient collect physician devote entirely guide patient , coordinate test perform , record information database . Data collect previously design specific collection data notebook . Sample size assessment specify number participant participant year necessary demonstrate effect . Estimating sample size data analysis : It expect able show difference favor active treatment main variable , namely , reduction triglyceride value end follow-up period ( 48 week ) least 20 % magnitude , comparison mean adjust covariance analysis . According estimate standard deviation 86 data , consistent literature data ( AIDS 1999 , 13:1424-1425 ) , magnitude minimum effect pre-defined relevant ( 20 % reduction ) , would enough 29 evaluable patient per group . It intend recruit patient forecast possible expected loss 10 % , word , 33 subject per group . Re-estimation sample size : Since variability estimate data situation ( pre-treatment baseline data ) , concrete data experimental situation ( variability DHA treatment ) , predefined protocol perform re-estimation sample size obtain follow 50 % 4 week treatment triglyceride value . To objective data main variable , triglyceride level baseline 4 week post-treatment , along random assignment mask code provide second independent statistical group ( Catalan Institute Oncology , Department Epidemiology Cancer Registration . Statistician : Dr. Victor Moreno ) respect central statistical analysis study ( Laboratory Biostatistics Epidemiology ( LBE ) , Section Clinical Trials , Autonomous University Barcelona . Statistician : Dr. Ferran Torres ) . This new group perform analysis , reveal variability data recalculate sample size . If sample size less expect , maintain accord initial design . Under circumstance significance test perform study prematurely stop secondarily re-estimate variability . According method , need adjustment multiplicity . Plan miss data address situation variable report miss , unavailable , `` non-reported , '' uninterpretable , consider miss data inconsistency out-of-range result Treatment miss value The main analysis intention treat require use subject without relevant deviation selection criterion , take least one dose study medication evaluation main variable prospectively , least three month follow . Under assumption , expect 1-year study follow find subject measurement make . Therefore set imputation miss value main variable follow : - If lack data due problem efficiency , cause unknown , shall attribute 95 % percentile value study group . - In case miss data reason , implement LOCF ( Last Observation Carried Forward ) method provide availability value least three month baseline measurement . The detailed procedure include statistical report plan evaluate consistency method close database meeting anonymous listing facilitate evaluation 'Blind Review ' procedure may re-evaluated ( CPMP/EWP/1776/99 : Points Consider Missing Data ) . Difficulties limitation study : The number patient peculiar management , due additional test perform , make study inevitably complex . However , physician permanently coordinate patient test perform . In addition , research team wide concrete synergistic function researcher . Finally , researcher constitute consolidated group experience previous study similar requirement . Statistical analysis plan describe analytical principle statistical technique employ order address primary secondary objective , specify study protocol plan . Statistical analysis Descriptive analysis The following descriptive index detail statistical report accord nature variable : - In continuous variable : Mean , CI 95 % , SD , minimum , P25 , median , P75 , max , N miss . Per group globally . - In categorical variable : % total respect column , N category . Per group globally . - In ordinal variable : They describe two table : one descriptive parameter continuous variable categorical variable . In open field interested list case one variable , described list . Inferential analysis The statistical treatment primary secondary efficacy variable specifically describe section . For variable , appropriate hypothesis test apply accord nature : Fisher exact test categorical variable , Student test continuous variable , Mann-Whitney U test ordinal variable . Basal homogeneity group An analysis baseline comparability treatment group establish regard demographic variable , risk factor clinical characteristic time inclusion . Main efficacy analysis The main variable efficacy evaluate compare difference baseline end value different treatment use ANCOVA model baseline value test covariate . Adjusted mean calculate confidence interval 95 % ( 95 % ) ANCOVA model . As main decision criterion efficacy contrast adjust mean endpoint study two treatment group perform . Additionally exploratory intent , shall evaluate compare effect different time observation . No multiplicity adjustment make due exploratory nature second analysis . In case relevant deviation case pursuant parametric test , apply nonparametric approach use transformation range correspond variable . The main analysis efficacy do population intend treat . However , evidence sensitivity robustness result , analysis protocol approach provide . Tolerability acceptability test All patient randomize treat include safety analysis . The frequency appearance adverse event two group compare use Fisher 's exact test . Level significance In proposed statistical test level significance require shall conventional ( p &lt; 0.05 bilateral ) . No provision make perform multiplicity adjust except intermediate analysis .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>1 . Serologic evidence HIV1 . 2 . Plasma triglycerides &gt; 2.26 mmol/L ( 200 mg/dL ) and/or Total Cholesterol &gt; 6 mmol/L ( 232 mg/dL ) measure fasting period least 12 hour confirm least two measure separate least interval one week . 3 . Body mass index 25 30 kg/m2 . 4 . Absence NSAIDs , antihypertensive drug , lipidlowering drug treatment medication know affect plasma lipid level . 5 . Alcohol intake &lt; 20 g/day . 6 . Absence Diabetes mellitus obesity ( BMI &gt; 30 ) 7 . Absence heart liver pathology ( within 3 month prior study ) . 8 . Absence renal failure ( serum creatinine &gt; 130 mmol/L ) Cr.Cl . &lt; 60 ml/min /1.73 m2 . 1 . Pregnancy absence adequate contraception childbearing age woman . 2 . Presence fail fulfil one condition list paragraphs 28 inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>DHA</keyword>
	<keyword>Omega 3</keyword>
	<keyword>Polyunsaturated Fatty Acids</keyword>
	<keyword>Dyslipidemia induce HAART</keyword>
	<keyword>Lipid metabolic alteration</keyword>
	<keyword>HIV</keyword>
</DOC>